Patients self-reported whether they had previously tried the therapy, if the therapy improved their symptoms, and whether they experienced any associated side effects. Idiopathic, diabetic, PSGp, and CTGp groups reported no side effects after pyloric botulinum injection. Current treatment options for gastroparesis are limited and options may be further limited for patients with atypical gastroparesis due to associated side effects.Table 1. Data is represented as number of patients (percentages) Metoclopramide Domperidone Erythromycin Botulinum toxin Idiopathic (n=149)  Previously tried 83 (55.7%) 32 (21.5%) 34 (22.8%) 21 (14.1%)  Symptoms improved 20 (24.1%) 13 (40.6%) 4 (11.8%) 9 (42.9%)  Experienced side effects 40 (48.2) 5 (15.6) 4 (11.8%) 0 (0.0%) Diabetic (n=60)  Previously tried 42 (70.0%) 14 (23.3%) 11 (18.3%) 14 (23.3%)  Symptoms improved 16 (38.1%) 7 (50.0%) 4 (36.4%) 1 (7.1%)  Experienced side effects 12 (28.6%) 0 (0.0%) 1 (9.1%) 0 (0.0%) Postsurgical (n=29)  Previously tried 17 (58.6%) 7 (24.1%) 8 (27.6%) 6 (20.7%)  Symptoms improved 3 (17.6%) 2 (28.6%) 2 (25.0%) 2 (33.3%)  Experienced side effects 7 (41.2%) 4 (57.1%) 4 (50.0%) 0 (0.0%) Connective tissue (n=13)  Previously tried 9 (69.2%) 2 (15.4%) 3 (23.1%) 5 (38.5%)  Symptoms improved 2 (22.2%) 0 (0.0%) 0 (0.0%) 1 (20.0%)  Experienced side effects 3 (33.3%) 1 (50.0%) 2 (66.7%) 0 (0.0%) Neurologic (n=5)  Previously tried 3 (60.0%) 3 (60.0%) 3 (60.0%) 1 (20.0%)  Symptoms improved 2 (66.7%) 2 (66.7%) 1 (33.3%) 0 (0.0%)  Experienced side effects 1 (33.3%) 1 (33.3%) 0 (0.0%) 1 (100.0%)